Tag: AGN
Argenica steps closer to clinical studies of stroke drug ARG-007 following positive preclinical safety results
Preclinical safety studies have been successfully completed for Argenica Therapeutics’ (ASX: AGN) stroke drug ARG-007, which paves the way for an ethics submission for a phase one clinical trial.
A...
Argenica Therapeutics toxicology studies indicate key findings ahead of ARG-007 clinical trial
Argenica Therapeutics (ASX: AGN) has announced results of recent in-life rodent and non-human primate toxicology studies, showing success in determining the maximum tolerated dose of ARG-007, required...
Argenica Therapeutics records positive results from ARG-007 study into cerebral ischaemia
Argenica Therapeutics (ASX: AGN) has recorded positive results from a pre-clinical study assessing the efficacy of lead candidate ARG-007 in protecting brain cells following cerebral ischaemia (or blo...
Argenica Therapeutics publishes scientific paper on ARG-007 ahead of clinical trials
Biotechnology company Argenica Therapeutics (ASX: AGN) has announced its chief scientific officer Professor Bruno Meloni has published a peer-reviewed paper on the company’s lead neuroprotective asset...
Argenica Therapeutics moves closer to clinical trials after completing genotoxicity studies on ARG-007
Argenica Therapeutics’ (ASX: AGN) upcoming clinical trials for its lead stroke treatment drug ARG-007 are a step closer with the company completing final good laboratory practice (GLP) genotoxicity st...
Argenica Therapeutics readies for phase 1 clinical trials of stroke drug
Argenica Therapeutics (ASX: AGN) is readying for phase 1 clinical trials of its stroke drug ARG-007, with pre-clinical study results anticipated throughout the current March quarter.
The company an...
Argenica Therapeutics completes pre-clinical toxicology studies of stroke drug
Biotech company Argenica Therapeutics (ASX: AGN) has announced the completion of preliminary pre-clinical toxicology studies and genotoxicity studies of its lead stroke treatment drug ARG-007.
The ...
Argenica Therapeutics secures experienced professional to lead clinical development of stroke drug
Biotechnology company Argenica Therapeutics (ASX: AGN) has added experienced healthcare and clinical trial professional Dr Meghan Thomas to its team to lead all clinical programs.
Dr Thomas has bee...
Argenica Therapeutics receives preliminary US patent approval for lead drug to treat stroke patients
The United States Patent and Trademark Office has issued a preliminary patent approval for Argenica Therapeutics’ (ASX: AGN) lead drug ARG-007 as a therapeutic treatment for patients of stroke, trauma...
Argenica Therapeutics reveals positive pre-clinical results of stroke drug ARG-007 in HIE
Argenica Therapeutics (ASX: AGN) has revealed positive efficacy results of its stroke drug ARG-007 during pre-clinical trials on animal models with hypoxic-ischaemic encephalopathy (HIE) – brain damag...
Argenica Therapeutics to start phase 1 clinical trials early next year
After extensive research and pre-clinical studies, Argenica Therapeutics (ASX: AGN) is gearing up to begin the phase 1 clinical trial for its stroke treatment drug ARG-007 in the first quarter of next...
Argenica Therapeutics commences preparations for phase 1 clinical trial of stroke-treatment drug ARG-007
Biotechnology company Argenica Therapeutics (ASX: AGN) has engaged Perth-based company Linear Clinical Research to initiate preliminary work required for a phase 1 trial into the safety and tolerabili...
Argenica Therapeutics produces GMP-grade ARG-007 for prevention of brain tissue death in stroke patients
Newly-listed biotech Argenica Therapeutics (ASX: AGN) has confirmed that two of its manufacturing partners have produced scaled-up, GMP-grade batches of its neuroprotective peptide candidate ARG-007 f...
Argenica Therapeutics prepares for clinical trials of novel stroke treatment
Developer of a novel treatment for stroke victims Argenica Therapeutics (ASX: AGN) has made its ASX debut today after a successful $7 million IPO.
With Alto Capital acting as the lead manager to th...
